Valuation: Insmed Incorporated

Market Cap 23.48B 20.52B 18.93B 17.45B 32.89B 2,261B 33.62B 226B 89.01B 1,107B 88.17B 86.24B 3,812B P/E 2026 *
-42.5x
P/E 2027 * 213x
Enterprise Value 22.91B 20.02B 18.48B 17.03B 32.1B 2,207B 32.81B 221B 86.87B 1,081B 86.05B 84.16B 3,720B EV / Sales 2026 *
13.5x
EV / Sales 2027 * 8.12x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day+0.80%
1 week-6.31%
Current month+1.59%
1 month+10.03%
3 months-25.03%
6 months-32.90%
Current year-37.76%
1 week 105.07
Extreme 105.07
115.55
1 month 95.27
Extreme 95.27
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.16
Extreme 20.164
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
6/25/26 Fiscal year

Chief Executive Officer

64,194 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
+0.80%-6.31%+3.98%+423.29% 23.29B
-7.17%-4.39%+45.51%+79.00% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
-0.09%-0.01%-17.62%-14.67% 23.15B
-5.95%-2.58%+30.67%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-5.16%-7.00%+168.44%+306.37% 16.09B
-6.91%-5.83%+26.53%+636.97% 15.93B
+0.43%-1.03%+24.63%+191.40% 14B
+1.46%+3.13%+58.71%+148.16% 12.58B
Average -2.35%+0.19%+42.57%+180.24% 25.31B
Weighted average by Cap. -2.70%-0.54%+41.49%+144.95%

Financials

2026 *2027 *
Net sales 1.7B 1.48B 1.37B 1.26B 2.38B 163B 2.43B 16.36B 6.44B 80.06B 6.37B 6.23B 276B 2.77B 2.42B 2.23B 2.06B 3.88B 267B 3.97B 26.71B 10.5B 131B 10.41B 10.18B 450B
Net income -560M -490M -452M -417M -785M -53.97B -803M -5.4B -2.12B -26.43B -2.1B -2.06B -90.99B 70.56M 61.66M 56.9M 52.45M 98.86M 6.8B 101M 680M 268M 3.33B 265M 259M 11.46B
Net Debt -566M -494M -456M -420M -792M -54.46B -810M -5.45B -2.14B -26.67B -2.12B -2.08B -91.82B -983M -859M -793M -731M -1.38B -94.67B -1.41B -9.48B -3.73B -46.37B -3.69B -3.61B -160B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-17 US$108.32 +0.80% 2,002,677
26-07-16 US$107.46 -2.14% 2,754,212
26-07-15 US$109.81 -0.27% 2,116,813
26-07-14 US$110.11 +0.89% 1,848,330
26-07-13 US$109.14 -5.60% 2,825,240
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
108.32USD
Average target price
196.38USD
Spread / Average Target
+81.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock